Biotechnology

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

November 25, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced advances in MINT-AD, the Multimodal Interpretable Transformer for Alzheimer's. Leveraging data from the Health and Retirement Study (HRS) International Family of Studies, IGC Pharma aims to identify unknown socioeconomic risk factors and their...

Read more

Bulletin from The Extraordinary General Meeting in Alligator Bioscience AB

November 25, 2025 6:00 AM

Alligator Bioscience (STO:ATORX) - Today, on 25 November 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below. Resolution on (A) amendment of the Articles of Association; and (B) decrease of the share capital to cover loss The meeting resolved to amend § 4 of the Articles of Association so that the limits for the share capital in the company are changed. The meeting...

Read more

Inside Information: Faron Intends to Issue Second Tranche of Bonds with an Aggregated Principal Amount of Eur 10 Million Under Its Convertible Bond Arrangement

November 24, 2025 12:30 PM

Faron Pharmaceuticals Ltd. (AIM:FARN, First North: FARON, "Faron" or the "Company"), a clinical-stage biopharmaceutical company developing novel immunotherapies, announced on 3 April 2025 that the Company has entered into a subscription agreement (the "Subscription Agreement") with an entity managed by Heights Capital Management, Inc. ("HCM") regarding the issuance and subscription of amortising senior unsecured convertible bonds with an...

Read more

Minutes from Extraordinary General Meeting in FluoGuide A/S

November 24, 2025 10:30 AM

FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025. To the shareholders of FluoGuide A/S. The Extraordinary General Meeting was held Monday 24 November 2025 at 10:00 AM (CET) at the Company's premises Titangade 13B, DK-2200 Copenhagen N, Denmark. Notice: Represented at the annual general meeting was share capital of nominal DKK 598,898.90 corresponding to 5,988,989 votes and 36.6% of...

Read more

Edison Oncology Presents New Clinical and Preclinical Data for EO1001 in ErbB‑Driven Tumors and EO‑4426 in CDA‑High Cancers at SNO 2025

November 24, 2025 9:00 AM

Edison Oncology Holding Corp. ("Edison Oncology" or "the Company") today announced the presentation of new clinical and preclinical data for two of its precision-oncology drug candidates-EO1001, an irreversible pan-ErbB inhibitor, and EO4426 (tezacitabine), a dual DNA polymerase-α and ribonucleotide reductase inhibitor-at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. Together, the presentations underscore Edison Oncology's leadership...

Read more

NDT Pharmaceuticals' Subsidiary, Good Salt(TM) Life, Secures Major Government Contract, Deploying Advanced Biosafety Ecosystem in Tennessee State Prisons

November 24, 2025 9:00 AM

NDT Pharmaceuticals Inc. (OTC:NDTP), a company focused on advancing sustainable health and wellness solutions, today announced a significant contract win for its wholly-owned subsidiary, Good Salt™ Life, LLC. The Tennessee Department of Correction (TDOC) has purchased Good Salt Life's ByoCart Sprayer units, Clean Republic Disinfectant to modernize hygiene and infection-control protocols across its correctional facilities, representing another...

Read more

Invitation to FluoGuide A/S (Nasdaq: FLUO) Webcast on 27 November 2025

November 24, 2025 5:30 AM

FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025. The following event will take place later that day: A live webcast for shareholders, analysts, investors and representatives of the media: Topic: FluoGuide Operational and Financial Results for Q3 2025 Date: Thursday 27 November 2025 Time: 14.00 CET The webcast is hosted by analyst Christian Binder, Redeye. FluoGuide is represented by...

Read more

Thrive Pet Healthcare and Empyrean Medical Systems Partner to Bring Human-Grade Precision to Veterinary Cancer Care With the Sirius(TM) Advanced Radiation Platform

November 20, 2025 6:00 PM

Empyrean Medical Systems, a pioneer in next-generation radiation oncology technology, today announced a strategic partnership with Thrive Pet Healthcare, one of the nation's leading veterinary networks, to bring the Sirius™ robotically accelerated conformal beam radiation platform to the veterinary oncology community. Opening in early 2026, PetCure Oncology, located onsite at the Veterinary Specialty Center of Seattle, will debut the first...

Read more

ClearPoint Neuro Completes Acquisition of IRRAS

November 20, 2025 5:00 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has completed its previously announced acquisition of IRRAS Holdings, Inc. ("IRRAS"). The transaction closed on November 20, 2025 following receipt of IRRAS shareholder approval and satisfaction or waiver of all required closing conditions. Under the terms of...

Read more

Vicore to Present at the DNB Carnegie Nordic Healthcare Conference

November 20, 2025 2:20 AM

Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the DNB Carnegie Nordic Healthcare Conference: Location: Oslo, Norway Format: Presentation and 1×1 meetings Presentation Date and Time: Tuesday, November 25 at 3:35 PM CET Participant: Hans Jeppsson, CFO The company's management team will also be available for meetings...

Read more

BurCell(R) Technologies and eFACTOR3 Partner to Advance Waste-to-Fuel Solutions

November 19, 2025 10:00 AM

BurCell® Technologies, a leader in sustainable waste management and renewable energy solutions, today announced a strategic partnership with eFACTOR3, a premier supplier of custom recycling equipment and integrated systems. This collaboration combines eFACTOR3's advanced waste processing technologies with BurCell's proprietary system to create a comprehensive solution that converts municipal solid waste into renewable fuels. The partnership...

Read more

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

November 19, 2025 8:45 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has executed a 4-month extension of its collaboration with The Scripps Research Institute ("Scripps Research") and the lab of Dr. Alexey Stepanov, Institute Investigator at Scripps Research effective November 1, 2025, to advance the...

Read more

Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board

November 18, 2025 5:35 PM

Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents under its profile on SEDAR+ (www.sedarplus.ca): Amended & restated management's discussion & analysis and officers' certificates for the year ended December 31, 2024; Amended & restated management's discussion & analysis and officers' certificates for the three months ended March 31, 2025; Amended &...

Read more

BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors

November 18, 2025 8:15 AM

BioInvent International (STO:BINV): Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with HER2-positive breast and gastric cancers A favorable clinical safety profile and early signs of efficacy further support the potential of FcγRIIB-blocking monoclonal antibodies in multiple solid tumors BioInvent remains focused on BI-1206, its lead FcγRIIB‑blocking antibody, and BI-1808, its...

Read more

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

November 17, 2025 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced financial results for the quarter ended September 30, 2025 (Second Quarter of Fiscal Year 2026) and provided a compelling update on its accelerated clinical and strategic progress. Q2 FY 2026 Strategic and Operational...

Read more

EMA Positive Opinion for Orphan Drug Designation to BioInvent's BI‑1808 for the Treatment of Cutaneous T-cell Lymphoma

November 17, 2025 3:15 AM

BioInvent International AB ("BioInvent")(Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has adopted a positive opinion for Orphan Drug Designation (ODD) to the company's investigational medicinal product...

Read more

Vicore to Present at The Jefferies Global Healthcare Conference in London

November 17, 2025 2:20 AM

Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Jefferies Global Healthcare Conference in London: Location : London, UK Format : Presentation and 1×1 meetings Presentation Date and Time : Tuesday, November 18 at 12:30 PM GMT Webcast : Registration Participants : Ahmed Mousa, CEO, Hans Jeppsson, CFO, and Jimmie...

Read more

BrYet US, Inc. Expands Patent Portfolio with New U.S. Patent for Targeted Drug Delivery

November 14, 2025 10:45 AM

BrYet US, Inc. - a biotechnology innovator focused on developing curative therapies for advanced cancers - announced today that it has expanded its patent portfolio with the issuance of U.S. Patent No. 12,390,420, titled "Compositions for Targeted Delivery of Therapeutic Agents and Methods for the Synthesis and Use Thereof." The patent covers compositions and methods intended to guide therapies to target tissues and control their release using...

Read more

Aspira Announces Third Quarter 2025 Financial Results and Provides Business Update

November 14, 2025 7:35 AM

Aspira Women's Health Inc. ("Aspira") (OTCQX:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and nine-month periods ended September 30, 2025. September Q3 Highlights: Aspira reported relatively flat total product revenues of $2.3 million for the third quarters of 2025 and...

Read more

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

November 13, 2025 5:00 PM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received an unfavorable decision from the U.S. Food & Drug Administration ("FDA") in response to its supervisory appeal of the not-approvable letter it received on August 19, 2025 in response to its Premarket Approval (PMA) application for VenoValve®, a surgical...

Read more